These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 19960790)

  • 41. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
    King TE; Brown KK; Raghu G; du Bois RM; Lynch DA; Martinez F; Valeyre D; Leconte I; Morganti A; Roux S; Behr J
    Am J Respir Crit Care Med; 2011 Jul; 184(1):92-9. PubMed ID: 21474646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of ambulatory oxygen on exertional dyspnea in IPF patients without resting hypoxemia.
    Nishiyama O; Miyajima H; Fukai Y; Yamazaki R; Satoh R; Yamagata T; Sano H; Iwanaga T; Higashimoto Y; Nakajima H; Kume H; Tohda Y
    Respir Med; 2013 Aug; 107(8):1241-6. PubMed ID: 23806287
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
    Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
    Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Repurposing of gamma interferon via inhalation delivery.
    Smaldone GC
    Adv Drug Deliv Rev; 2018 Aug; 133():87-92. PubMed ID: 29886069
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhaled recombinant interferon gamma in patients with lung cancer: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages and peripheral blood neutrophils and monocytes.
    Halme M; Maasilta P; Repo H; Ristola M; Taskinen E; Mattson K; Cantell K
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):93-101. PubMed ID: 7995773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic value of clinical exercise testing in idiopathic pulmonary fibrosis].
    Wallaert B; Guetta A; Wemeau-Stervinou L; Tercé G; Valette M; Nevière R; Aguilaniu B
    Rev Mal Respir; 2011 Mar; 28(3):290-6. PubMed ID: 21482330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
    Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
    Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interferon-gamma 1b for the treatment of idiopathic pulmonary fibrosis.
    Bouros D; Antoniou KM; Tzouvelekis A; Siafakas NM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1051-60. PubMed ID: 16989587
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of systemic sclerosis with gamma-interferon.
    Hein R; Behr J; Hündgen M; Hunzelmann N; Meurer M; Braun-Falco O; Urbanski A; Krieg T
    Br J Dermatol; 1992 May; 126(5):496-501. PubMed ID: 1610690
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of gamma interferon on lung function of mustard gas exposed patients, after 15 years.
    Ghanei M; Panahi Y; Mojtahedzadeh M; Khalili AR; Aslani J
    Pulm Pharmacol Ther; 2006; 19(2):148-53. PubMed ID: 16137903
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Usefulness of whole-blood interferon-gamma assay and interferon-gamma enzyme-linked immunospot assay in the diagnosis of active pulmonary tuberculosis.
    Kang YA; Lee HW; Hwang SS; Um SW; Han SK; Shim YS; Yim JJ
    Chest; 2007 Sep; 132(3):959-65. PubMed ID: 17505029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review.
    Corte TJ; Wort SJ; Wells AU
    Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(1):7-19. PubMed ID: 19960783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant interferon gamma in patients with pulmonary atypical Mycobacteriosis: a randomized, double-blind, placebo-controlled study.
    Milanés-Virelles MT; García-García I; Santos-Herrera Y; Valdés-Quintana M; Valenzuela-Silva CM; Jiménez-Madrigal G; Ramos-Gómez TI; Bello-Rivero I; Fernández-Olivera N; Sánchez-de la Osa RB; Rodríguez-Acosta C; González-Méndez L; Martínez-Sánchez G; López-Saura PA;
    BMC Infect Dis; 2008 Feb; 8():17. PubMed ID: 18267006
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Subcutaneous administration of interferon alpha and gamma in patients with metastatic renal cell carcinoma.
    Koga S; Nishikido M; Matsuya F; Kanetake H; Saito Y
    Anticancer Res; 1999; 19(6C):5547-50. PubMed ID: 10697614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.
    van den Blink B; Dillingh MR; Ginns LC; Morrison LD; Moerland M; Wijsenbeek M; Trehu EG; Bartholmai BJ; Burggraaf J
    Eur Respir J; 2016 Mar; 47(3):889-97. PubMed ID: 26869678
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Final results of a double-blind, placebo-controlled trial of the antifibrotic efficacy of interferon-gamma1b in chronic hepatitis C patients with advanced fibrosis or cirrhosis.
    Pockros PJ; Jeffers L; Afdhal N; Goodman ZD; Nelson D; Gish RG; Reddy KR; Reindollar R; Rodriguez-Torres M; Sullivan S; Blatt LM; Faris-Young S
    Hepatology; 2007 Mar; 45(3):569-78. PubMed ID: 17326152
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis.
    Honoré I; Nunes H; Groussard O; Kambouchner M; Chambellan A; Aubier M; Valeyre D; Crestani B
    Am J Respir Crit Care Med; 2003 Apr; 167(7):953-7. PubMed ID: 12663336
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vibration response imaging in idiopathic pulmonary fibrosis: a pilot study.
    Liu QX; Guan WJ; Xie YQ; An JY; Jiang M; Zhu Z; Guo E; Yu XX; Liu WT; Gao Y; Zheng JP
    Respir Care; 2014 Jul; 59(7):1071-7. PubMed ID: 24129336
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.
    Kim TH; Lee YH; Kim KH; Lee SH; Cha JY; Shin EK; Jung S; Jang AS; Park SW; Uh ST; Kim YH; Park JS; Sin HG; Youm W; Koh ES; Cho SY; Paik YK; Rhim TY; Park CS
    Am J Respir Crit Care Med; 2010 Sep; 182(5):633-42. PubMed ID: 20463180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Change in serum marker of oxidative stress in the progression of idiopathic pulmonary fibrosis.
    Matsuzawa Y; Kawashima T; Kuwabara R; Hayakawa S; Irie T; Yoshida T; Rikitake H; Wakabayashi T; Okada N; Kawashima K; Suzuki Y; Shirai K
    Pulm Pharmacol Ther; 2015 Jun; 32():1-6. PubMed ID: 25862941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.